Maria Onoya, MD
Internal Medicine · Athens, ALNPI 1801237946
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,328 of the $5,999 with a category attached, or 88.8%. 27 manufacturers reported payments, led by AstraZeneca at 32.1% of the total. Reporting peaked in 2019 at $1,362 and has fallen 85.7% since, to $195 in 2025.
Across 278 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$849
- AbbVie$822
- Lilly USA, LLC$522
- Pfizer$284
- GSK$261
- plus $1K from 21 others
Across 12 payments — averaging $6545.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$79K
What the payments were for
- Consulting fees$65011%
- Food & beverage$5,32889%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $1,926 |
| Novo Nordisk | 39 | $849 |
| AbbVie(2 entities) | 57 | $822 |
| Lilly USA, LLC | 33 | $522 |
| Pfizer | 19 | $284 |
| GSK | 16 | $261 |
| Revance Therapeutics, Inc. | 7 | $196 |
| Amgen | 10 | $161 |
| Abbott | 5 | $97 |
| Johnson & Johnson | 4 | $86 |
| Bayer | 4 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Novartis | 3 | $68 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Supernus Pharmaceuticals, Inc. | 4 | $55 |
| Intra-sana Laboratories | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,999 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 43 | $42,278 |
| FarxigaDapagliflozin Propanediol | 32 | $23,462 |
| JardianceEmpagliflozin | 22 | $22,685 |
| MounjaroTirzepatide | 16 | $21,828 |
| LinzessLinaclotide | 25 | $19,610 |
| OzempicSemaglutide | 18 | $19,521 |
| TrulicityDulaglutide | 17 | $17,726 |
| MyrbetriqMirabegron | 20 | $14,848 |
| RybelsusSemaglutide | 12 | $13,336 |
| XareltoRivaroxaban | 15 | $12,223 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $9,895 |
| JanuviaSitagliptin Phosphate | 16 | $9,648 |
| BelsomraSuvorexant | 11 | $4,768 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $4,185 |
| Duloxetine Hcl | 92 | $2,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $284 | $42,27843 claims |
| Lilly USA, LLCMounjaro, Trulicity | $522 | $39,55433 claims |
| Novo NordiskOzempic, Rybelsus | $849 | $32,85730 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $20 | $32,58042 claims |
| AstraZenecaFarxiga | $1,926 | $23,46232 claims |
| AbbVieLinzess | $822 | $19,61025 claims |
| Johnson & JohnsonXarelto | $86 | $12,22315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Athens
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
- Justin HoveyDothan$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.